Virpax Pharmaceuticals(VRPX)
$0.000.00 (0.00%)
VRPX
Virpax Pharmaceuticals financials statements
$0.00
At close:0.00 (0.00%)
Want to see VRPX full AI Analyst Report?
Virpax Pharmaceuticals (VRPX) Ratios
216 Followers
Virpax Pharmaceuticals Ratios
VRPX's free cash flow for Q4 2024 was $-2.87M. For the 2024 fiscal year, VRPX's free cash flow was increased by $0.00 and operating cash flow was $-2.87M. See a summary of the company’s cash flow.
| Ratios | Dec 24 | Dec 23 | Dec 22 | Mar 22 | Dec 20 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.63 | 1.25 | 6.36 | 18.96 | 0.02 |
| Quick Ratio | 0.63 | 1.25 | 6.36 | 18.96 | 0.02 |
| Cash Ratio | 0.61 | 1.19 | 6.14 | 17.65 | 0.01 |
| Solvency Ratio | -4.89 | -1.91 | -1.01 | -0.06 | -0.06 |
| Operating Cash Flow Ratio | -6768.07 | -1.28 | -5.77 | -6.97 | -0.38 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | -2.55 |
| Net Current Asset Value | $ -913.76K | $ 1.93M | $ 16.58M | $ 37.48M | $ -4.61M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 3.36 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -0.37 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -0.59 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -0.32 |
| Financial Leverage Ratio | -1.70 | 4.98 | 1.19 | 1.06 | -0.11 |
| Debt Service Coverage Ratio | -115.31 | 0.00 | 0.00 | 0.00 | 0.01 |
| Interest Coverage Ratio | -116.43 | 0.00 | 0.00 | -129.55 | -28.36 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.02 | 0.00 | 0.00 | 0.08 | 3.47 |
| Net Debt to EBITDA | 0.13 | 0.62 | 0.00 | 0.00 | 377.70 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 99.10% | 100.77% | 103.41% |
| EBT Per EBIT | 99.89% | 96.81% | 99.11% | 100.25% | 103.43% |
| Return on Assets (ROA) | -775.72% | -157.76% | -109.06% | -30.70% | -964.23% |
| Return on Equity (ROE) | 1320.61% | -785.26% | -129.42% | -32.41% | 106.44% |
| Return on Capital Employed (ROCE) | 1322.00% | -811.13% | -131.76% | -32.08% | 131.34% |
| Return on Invested Capital (ROIC) | 1322.00% | -811.13% | -131.76% | -32.08% | 158.30% |
| Return on Tangible Assets | -775.72% | -157.76% | -109.06% | -30.70% | -964.23% |
| Earnings Yield | -29.86% | -16.21% | -11.78% | -1.21% | -0.56% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -3928.38 | -8.41 | -15.24 | -12.41 | -2.80 |
| Free Cash Flow Per Share | -3928.38 | -8.41 | -15.24 | -12.41 | -2.80 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -0.88 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -41351.34% | -10.52% | -9.80% | -1.45% | -0.17% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.13 | -6.17 | -8.49 | -82.69 | -179.90 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -44.23 | 48.44 | 10.99 | 26.80 | -191.48 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.00 | -9.51 | -10.20 | -69.08 | -582.94 |
| Price-to-Operating Cash Flow Ratio | -0.00 | -9.51 | -10.20 | -69.08 | -582.94 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | 0.21 | -0.11 | -5.77 | -4.75 |
| Enterprise Value Multiple | -3.25 | -5.76 | 0.00 | 0.00 | 202201.63 |
| Enterprise Value | 38.90M | 84.56M | 163.13M | 967.71M | 808.81M |
| EV to EBITDA | -3.25 | -5.76 | 0.00 | 0.00 | 202201.63 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -0.00 | -8.58 | -9.14 | -66.54 | -584.03 |
| EV to Operating Cash Flow | -0.00 | -8.58 | -9.14 | -66.54 | -584.03 |
| Tangible Book Value Per Share | -0.21 | 1.65 | 14.16 | 32.00 | -8.53 |
| Shareholders’ Equity Per Share | -0.21 | 1.65 | 14.16 | 32.00 | -8.53 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -2.84 | -12.97 | -18.32 | -10.37 | -9.07 |
| Tax Burden | 1.00 | 1.00 | 0.99 | 1.01 | 1.03 |
| Interest Burden | 1.01 | 1.00 | 1.00 | 1.01 | 1.04 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1384.98 | 0.65 | 0.82 | 1.21 | 0.32 |
Currency in USD
